Regeneron’s (REGN) pipeline products have still a lot of good news to announce. The latest is about its product Dupixant (dupilumab) which has already been FDA approved for atopic dermatitis. Now, there are reasons to believe that this drug could be also approved as an add-on maintenance for people with moderate to severe Asthma.

The news has come from both Regeneron and its partner Sanofi (SNY), stating that they have filed a supplemental Biologics License Application (sBLA) for the new Dupixant indication, which is asthma. The product has yet to be approved . . .